NMD Pharma Announces Topline Results from Phase 2a CMT Study
NMD Pharma reported topline Phase 2a results from SYNAPSE-CMT, a randomized, double-blind, placebo-controlled study of ignaseclant, its first-in-class skeletal...
Ignaseclant CMT Trial: NMD Pharma Announces Topline Results
NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot-Marie-Tooth disease (CMT) types 1 and 2. The randomized,...
Novo Nordisk Reveals Promising 2026 Sales, Profit Outlook
Novo Nordisk posted 2025 constant-currency sales growth of 10% and operating profit growth of 6%, in line with guidance,...
Novartis Delivered Strong Sales Growth & 40% Margin in 2025
Novartis posted full-year 2025 net sales of $54.5 billion, up 8% at constant currency, with core operating income rising...
Beghou Names Meredith Ressi President & Chief Growth Officer
Beghou has elevated Meredith Ressi to President and Chief Growth Officer, expanding her remit from growth to end-to-end client...
Pharma Co. Expands Arakoda Access with GoodRx Partnership
60 Degrees Pharmaceuticals has partnered with GoodRx to offer up to 30% savings on Arakoda (tafenoquine), the once-weekly, FDA‑approved...
Announcing Cormedix Therapeutics Share Repurchase Program
CorMedix Therapeutics has authorized a share repurchase program of up to $75 million through December 31, 2027, with purchases...
Spectral AI Announces Burn Awareness Week 2026 Participation
Spectral AI will join the American Burn Association’s National Burn Awareness Week, aligning a workplace-focused prevention campaign with its...
Harrow Reaffirms Strong 2025 Revenue Growth Guidance
Harrow reaffirmed its 2025 revenue guidance of $270–280 million and outlined an aggressive commercial ramp across its ophthalmology portfolio....
Breakthru Medicine Emerges With $60M to Develop Cancer Drugs
Breakthru Medicine has emerged from stealth with a $60 million Series A following a prior undisclosed seed round, aiming...